



Studies on synthesis and characterization of bio-active 1,3,5-triazine derivatives

Himanshu D. Patel¹, Keshav C. Patel^{2,*}, Kalpesh M. Mehta², Paresh S. Patel³ and Lina A. Patel⁴

¹Department of Chemistry, Silvassa Institute of Higher Learning, A Government Aided College of Arts, Commerce and Science, DNHUSS, Silvassa – Naroli – 396235 (U. T. of D & NH) India

²Department of Chemistry, Veer Narmad South Gujarat University, Udhna-Magdalla Road, Surat – 395007, Gujarat, India.

³Department of Chemistry, Narmada College of Science and Commerce, Zadeshwer, Bharuch - 392011, Gujarat, India.

⁴Department of Chemistry, C. U. Shah Science College, Ashram Road, Ahmedabad – 380014, Gujarat, India.

ARTICLE INFO

Article history:

Received: 4 March 2013;

Received in revised form:

17 April 2013;

Accepted: 3 May 2013;

Keywords

Synthesis,
Characterization,
Schiff's base,
Azetidinone,
Thiazolidinone,
Antimicrobial activity.

ABSTRACT

Series of compounds containing *s*-triazine derivatives were synthesized. The synthetic strategy utilizes cyanuric chloride as a starting material to obtain the several Schiff's base A(1-5), azetidinone B(1-5) and thiazolidinone C(1-5) viz. condensations and cyclizations. All newly synthesized compounds have been characterized by physical processes (melting points, Thin layer chromatography, elemental analysis, IR and NMR spectra) and have been tested for their antimicrobial activity against gram (+)ve and gram (-)ve bacteria and also on different stains of fungi in which some of these derivatives exhibited potential antibacterial and antifungal activity.

© 2013Elixir All rights reserved.

Introduction

Among a wide variety of heterocyclic that have been explored for developing pharmaceutical important molecules such as 1,3,5-triazine, Schiff's base, azetidinone, thiazolidinone have played an important role in medicinal chemistry. As a reagent in organic synthesis, 1,3,5-triazine is used as the equivalent of hydrogen cyanide (HCN). One application is in the Gattermann reaction, used to attach the formyl group to aromatic substrates.^[1] It is a common reagent, and readily forms derivatives, which are used as herbicides, dyes, polymers but pharmacological applications are most important.^[2,3] Several derivatives of *s*-triazine show antimicrobial^[4,5], antitubercular^[6] and anti-HIV activity^[7]. They are used as a potential hormone receptor antagonists, anti-tryposomal drugs^[8], anti-malarial activity^[9], antitumor activity^[10], Cyclin Dependent Kinase (CDK) inhibitor^[11] and photosynthesis inhibiting activity^[12]. In this entire work deals with studies on synthesis and characterization of bio-active 1,3,5-triazine derivatives having the route shown in experimental section.

Experimental

All the melting points reported are uncorrected and were recorded using an electro thermal melting point apparatus. Thin layer chromatography was performed on Merck precoated 60 F₂₅₄ plates. Ethyl acetate : Benzene (7.5 : 2.5) was used as solvent for the TLC and the spots were rendered visible by exposing to UV light. IR spectra were recorded on Shimadzu FT-IR (Japan) instrument. ¹H NMR spectra were recorded on Bruker Avance II NMR spectrometer. Chemical shifts (δ ppm) reported are referred to internal reference TMS. Elemental analyses were obtained using a Carlo-Erba CHNS-O EA 1108

elemental analyzer. 1,3,5-triazine was received from Atul limited, Valsad (Gujarat) India. Synthetic route are described in Scheme-I and Scheme-II.

Synthesis of 2,4-dichloro-6-(4-methylphenoxy)-1,3,5-triazine (I)

To a stirred solution of 1,3,5-triazine (0.01mole, 1.81gm) in acetone (25 ml) at 0-5 °C, the solution of 4 - cresol (0.01mole, 1.09gm) in acetone (5 ml) was added and pH was maintained neutral by the addition of 10 % sodium carbonate solution. The stirring was continued at 0-5 °C for 4 hrs. After the completion of reaction, mixture was poured on ice cold water. The solid product obtained was filtered and dried. The crude product was purified by crystallization from acetone to give 2,4-dichloro-6-(4-methylphenoxy)-1,3,5-triazine.

Synthesis of 6-(4-methylphenoxy)-4-[4-(4-methoxyphenyl)-piperazine-1-yl]-2-(chloro)-1,3,5-triazine (II)

To a stirred solution of 2,4-dichloro-6-(4-methylphenoxy)-1,3,5-triazine (I) (0.01mole, 2.56gm) in acetone (10 ml) at 30-35 °C, the solution of 4-methoxy *N*-phenyl piperazine (0.01mole, 1.92gm) in acetone (5 ml) was added drop wise maintaining the temperature 35 °C. The pH was adjusted neutral by the addition of 10 % sodium bicarbonate solution. The temperature was gradually raised to 45°C during 2 hrs. After the completion of reaction, the resultant content was poured into ice cold water. The solid product obtained was filtered and dried to give 6-(4-methylphenoxy)-4-[4-(4-methoxyphenyl) piperazine-1-yl]-2-(chloro)-1,3,5-triazine (II).

Synthesis of 2-(2-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyloxy)-1,3,5-triazine^[13] (III)

Take a compound 6-(4-methylphenoxy)-4-[4-(4-methoxyphenyl)piperazine-1-yl]-2-(chloro)-1,3,5-triazine (0.01mole, 4.27gm) and hydrazine hydrate (0.05mole, 2.50gm) in alcohol (25 ml) was refluxed in a water bath. The temperature was gradually raised to 80-90 °C during 3 hrs. The pH was adjusted neutral by the addition of 10 % sodium bicarbonate solution. After the completion of reaction, the refluxed content was added to cold water. The solid product obtained was filtered and dried. The crude product was purified by crystallization from absolute alcohol.

Synthesis of 2-(2-substituted benzyldenehydrazinyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyloxy)-1,3,5-triazine^[14] (A₁ to A₅)

A mixture of 2-(methylphenoxy)-6-[4-(4-methoxyphenyl)piperazine-1-yl]-4-(hydrazino)-1,3,5-triazine (III) (0.01mole, 4.23gm) and substituted benzaldehyde (0.01mole) was dissolved in absolute ethanol (25 ml) and add few drops of glacial acetic acid. The reaction mixture was refluxed for 8 hrs in a water bath then cooled and poured into ice cold water, solid product obtained was filtered and dried.

2-(2-(4-chloro)benzyldenehydrazinyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyl oxy)-1,3,5-triazine (A₁)

Yield 82%; m.p. 148-150 °C; Anal. Calcd. for C₂₈H₂₈O₂N₇Cl (530.0 gm/mole): C, 63.45; H, 5.32; N, 18.50. Found: C, 63.51; H, 5.38; N, 18.59. IR (KBr, cm⁻¹): 784 (C-Cl), 815, 1365, 1440, 1580, 1620, 2980, 3150, 3200. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.38 (s, 3H, -CH₃), 3.10 (t, 4H, -N-CH₂), 3.78 (s, 3H, -OCH₃), 3.98 (t, 4H, -N-CH₂), 6.75-7.75 (m, 12H, Ar-H), 8.43 (s, 1H, -N-CH), 10.55 (s, 1H, -NH).

2-(2-(4-hydroxy)benzyldenehydrazinyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyl oxy)-1,3,5-triazine (A₂)

Yield 79%; m.p. 165-167 °C; Anal. Calcd. for C₂₈H₂₉O₃N₇ (511.57 gm/mole): C, 65.74; H, 5.71; N, 19.17. Found: C, 65.82; H, 5.64; N, 19.26. IR (KBr, cm⁻¹): 817, 1361, 1439, 1585, 1622, 2976, 3148, 3205, 3260 (O-H). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.41 (s, 3H, -CH₃), 3.20 (t, 4H, -N-CH₂), 3.65 (s, 3H, -OCH₃), 3.88 (t, 4H, -N-CH₂), 5.42 (s, 1H, -OH), 6.70-7.70 (m, 12H, Ar-H), 8.39 (s, 1H, -N-CH), 10.61 (s, 1H, -NH).

2-(2-(4-methoxy)benzyldenehydrazinyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyl oxy)-1,3,5-triazine (A₃)

Yield 77%; m.p. 164-166 °C; Anal. Calcd. for C₂₉H₃₁O₃N₇ (525.60 gm/mole): C, 66.27; H, 5.94; N, 18.65. Found: C, 66.39; H, 5.87; N, 18.58. IR (KBr, cm⁻¹): 820, 1369, 1445 (C-O-C), 1582, 1615, 2978, 3151, 3212. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.39 (s, 3H, -CH₃), 3.19 (t, 4H, -N-CH₂), 3.70 (s, 3H, -OCH₃), 3.95 (t, 4H, -N-CH₂), 4.02 (s, 3H, -OCH₃), 6.75-7.80 (m, 12H, Ar-H), 8.40 (s, 1H, -N-CH), 10.58 (s, 1H, -NH).

2-(2-(2,4-dichloro)benzyldenehydrazinyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyl oxy)-1,3,5-triazine (A₄)

Yield 85%; m.p. 180-182 °C; Anal. Calcd. for C₂₈H₂₇O₂N₇Cl₂ (546.64 gm/mole): C, 59.58; H, 4.82; N, 17.37. Found: C, 59.66; H, 4.91; N, 17.49. IR (KBr, cm⁻¹): 727 (C-Cl), 812, 1370, 1450, 1570, 1609, 2975, 3140, 3230. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.40 (s, 3H, -CH₃), 3.10 (t, 4H, -N-CH₂), 3.75 (s, 3H, -OCH₃), 3.90 (t, 4H, -N-CH₂), 6.70-7.80 (m, 11H, Ar-H), 8.35 (s, 1H, -N-CH), 10.62 (s, 1H, -NH).

2-(2-(3,4-dihydroxy)benzyldenehydrazinyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyloxy)-1,3,5-triazine (A₅)

Yield 80%; m.p. 103-105 °C; Anal. Calcd. for C₂₈H₂₉O₄N₇ (527.57 gm/mole): C, 63.74; H, 5.54; N, 18.58. Found: C,

63.68; H, 5.47; N, 18.49. IR (KBr, cm⁻¹): 816, 1372, 1443, 1575, 1615, 2980, 3145, 3222, 3270 (O-H). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.40 (s, 3H, -CH₃), 3.10 (t, 4H, -N-CH₂), 3.75 (s, 3H, -OCH₃), 3.90 (t, 4H, -N-CH₂), 5.30 (s, 1H, -OH), 5.65 (s, 1H, -OH), 6.70-7.80 (m, 11H, Ar-H), 8.35 (s, 1H, -N-CH), 10.62 (s, 1H, -NH).

Synthesis of 3-chloro-1-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyloxy)-1,3,5-triazin-2-ylamino)-4-(substitutedphenyl)azetidin-2-one (B₁ to B₅)

Take a solution of 2-(2-substituted benzyldenehydrazinyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyloxy)-1,3,5-triazine (A₁ to A₅) (0.01 mole) and triethylamine (5-6 drops) as a catalyst in dry benzene (15 ml) was added in chloro acetyl chloride (0.015 mole, 1.18gm) at 50 °C. The reaction mixture was stirred for a half an hour at room temperature and refluxed for 6-7 hrs, then cooled it and poured in ice cold water. The solid thus obtained was recrystallization from alcohol to yield the target compounds (B₁ to B₅).

3-chloro-1-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyloxy)-1,3,5-triazin-2-ylamino)-4-(4-chlorophenyl)azetidin-2-one (B₁)

Yield 82%; m.p. 138-140 °C; Anal. Calcd. for C₃₀H₂₉O₃N₇Cl₂ (602.10 gm/mole): C, 59.41; H, 4.82; N, 16.17. Found: C, 59.26; H, 4.90; N, 16.04. IR (KBr, cm⁻¹): 810 (C-Cl), 835, 1325, 1430, 1510, 1700, 3015, 3240. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.31 (s, 3H, -CH₃), 3.01 (t, 4H, -N-CH₂), 3.61 (s, 3H, -OCH₃), 3.81 (t, 4H, -N-CH₂), 4.61 (s, 1H, -CH-Cl), 5.90 (s, 1H, -N-CH), 6.78-7.84 (m, 12H, Ar-H), 9.51 (s, 1H, -NH).

3-chloro-1-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyloxy)-1,3,5-triazin-2-ylamino)-4-(4-hydroxyphenyl)azetidin-2-one (B₂)

Yield 73%; m.p. 110-112 °C; Anal. Calcd. for C₃₀H₃₀O₄N₇Cl (588.05 gm/mole): C, 61.27; H, 5.14; N, 16.67. Found: C, 61.18; H, 5.01; N, 16.76. IR (KBr, cm⁻¹): 842, 1330, 1440, 1520, 1710 (-C=O Azetidinone), 3015, 3240, 3280 (O-H). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.29 (s, 3H, -CH₃), 3.05 (t, 4H, -N-CH₂), 3.65 (s, 3H, -OCH₃), 3.80 (t, 4H, -N-CH₂), 4.58 (s, 1H, -CH-Cl), 5.38 (s, 1H, -OH), 5.88 (s, 1H, -N-CH), 6.72-7.80 (m, 12H, Ar-H), 9.47 (s, 1H, -NH).

3-chloro-1-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyl oxy)-1,3,5-triazin-2-ylamino)-4-(4-methoxyphenyl)azetidin-2-one (B₃)

Yield 72%; m.p. 154-156 °C; Anal. Calcd. for C₃₁H₃₂O₄N₇Cl (602.10 gm/mole): C, 61.84; H, 5.36; N, 16.28. Found: C, 61.74; H, 5.44; N, 16.36. IR (KBr, cm⁻¹): 835, 1334, 1445, 1521, 1730 (-C=O Azetidinone), 3020, 3238. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.31 (s, 3H, -CH₃), 3.13 (t, 4H, -N-CH₂), 3.52 (s, 3H, -OCH₃), 3.70 (s, 3H, -OCH₃), 3.95 (t, 4H, -N-CH₂), 4.63 (s, 1H, -CH-Cl), 5.95 (s, 1H, -N-CH), 6.71-7.81 (m, 12H, Ar-H), 9.58 (s, 1H, -NH).

3-chloro-1-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(p-tolyl oxy)-1,3,5-triazin-2-ylamino)-4-(2,4-dichlorophenyl)azetidin-2-one (B₄)

Yield 80%; m.p. 144-146 °C; Anal. Calcd. for C₃₀H₂₈O₃N₇Cl₃ (640.94 gm/mole): C, 56.22; H, 4.40; N, 15.30. Found: C, 56.30; H, 4.24; N, 15.39. IR (KBr, cm⁻¹): 830 (C-Cl), 830, 1340, 1452, 1523, 1727 (-C=O Azetidinone), 3013, 3240. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.40 (s, 3H, -CH₃), 3.07 (t, 4H, -N-CH₂), 3.48 (s, 3H, -OCH₃), 3.92 (t, 4H, -N-CH₂), 4.70 (s, 1H, -CH-Cl), 5.86 (s, 1H, -N-CH), 6.65-7.75 (m, 11H, Ar-H), 9.60 (s, 1H, -NH).

3-chloro-1-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(*p*-tolyl oxy)-1,3,5-triazin-2-ylamino)-4-(3,4-dihydroxyphenyl)azetidin-2-one (B₅)

Yield 75%; m.p. 218-220 °C; Anal. Calcd. for C₃₀H₃₀O₅N₇Cl (604.05 gm/mole): C, 59.65; H, 5.10; N, 16.23. Found: C, 56.59; H, 5.18; N, 16.03. IR (KBr, cm⁻¹): 832, 1341, 1456, 1525, 1732 (-C=O Azetidinone), 3015, 3253, 3270 (O-H). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.51 (s, 3H, -CH₃), 3.05 (t, 4H, -N-CH₂), 3.53 (s, 3H, -OCH₃), 3.89 (t, 4H, -N-CH₂), 4.71 (s, 1H, -CH-Cl), 5.15 (s, 1H, -OH), 5.45 (s, 1H, -OH), 5.90 (s, 1H, -N-CH), 6.70-7.84 (m, 11H, Ar-H), 9.65 (s, 1H, -NH).

Synthesis of 3-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(*p*-tolyl oxy)-1,3,5-triazin-2-ylamino)-2-(substitutedphenyl)thiazolidin-4-one (C₁ to C₅)

To a solution of 2-(2-substituted benzylidenehydrazinyl)-6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(*p*-tolyl oxy)-1,3,5-triazine (A₁ to A₅) (0.01mole) and 1gm of anhydrous zinc chloride as a catalyst in dry benzene (15 ml), thioglycolic acid (0.02mole, 1.84gm) was added by dropping funnel with stirring at constant temperature and refluxed it for 8-9 hrs, then cooled it and poured in sodium bicarbonate solution (10%) to get neutralized. The solid thus obtained was recrystallized from alcohol to yield target compounds (C₁ to C₅).

3-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(*p*-tolyl oxy)-1,3,5-triazin-2-ylamino)-2-(4-chlorophenyl)thiazolidin-4-one (C₁)

Yield 73%; m.p. 179-181 °C; Anal. Calcd. for C₃₀H₃₀O₃N₇SCl (604.12 gm/mole): C, 59.64; H, 5.01; N, 16.23. Found: C, 56.72; H, 5.13; N, 16.35. IR (KBr, cm⁻¹): 690, 750 (C-Cl), 813, 1300, 1380, 1510, 1698, 3050, 3250. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.31 (s, 3H, -CH₃), 2.75 (s, 2H, -S-CH₂), 3.10 (t, 4H, -N-CH₂), 3.75 (s, 3H, -OCH₃), 3.92 (t, 4H, -N-CH₂), 5.90 (s, 1H, -N-CH), 6.80-7.50 (m, 12H, Ar-H), 11.01 (s, 1H, -NH).

3-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(*p*-tolyl oxy)-1,3,5-triazin-2-ylamino)-2-(4-hydroxyphenyl)thiazolidin-4-one (C₂)

Yield 75%; m.p. 185-187 °C; Anal. Calcd. for C₃₀H₃₁O₄N₇S (604.12 gm/mole): C, 61.52; H, 5.34; N, 16.74. Found: C, 61.63; H, 5.42; N, 16.66. IR (KBr, cm⁻¹): 692, 815, 1305, 1378, 1515, 1690, 3050, 3250, 3275 (O-H). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.28 (s, 3H, -CH₃), 2.70 (s, 2H, -S-CH₂), 3.15 (t, 4H, -N-CH₂), 3.80 (s, 3H, -OCH₃), 3.95 (t, 4H, -N-CH₂), 5.40 (s, 1H, -OH), 5.95 (s, 1H, -N-CH), 6.70-7.40 (m, 12H, Ar-H), 11.10 (s, 1H, -NH).

3-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(*p*-tolyl oxy)-1,3,5-triazin-2-ylamino)-2-(4-methoxyphenyl)thiazolidin-4-one (C₃)

Yield 81%; m.p. 124-126 °C; Anal. Calcd. for C₃₁H₃₃O₄N₇S (599.70 gm/mole): C, 61.98; H, 5.70; N, 16.32. Found: C, 61.89; H, 5.83; N, 16.46. IR (KBr, cm⁻¹): 710, 825, 1320, 1380, 1525, 1695, 3040, 3205. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.32 (s, 3H, -CH₃), 2.71 (s, 2H, -S-CH₂), 3.20 (t, 4H, -N-CH₂), 3.60 (s, 3H, -OCH₃), 3.75 (s, 3H, -OCH₃), 3.99 (t, 4H, -N-CH₂), 5.90 (s, 1H, -N-CH), 6.70-7.50 (m, 12H, Ar-H), 11.05 (s, 1H, -NH).

3-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(*p*-tolyl oxy)-1,3,5-triazin-2-ylamino)-2-(2,4-dichlorophenyl)thiazolidin-4-one (C₄)


Yield 72%; m.p. 114-116 °C; Anal. Calcd. for C₃₀H₂₉O₃N₇Cl₂ (638.56 gm/mole): C, 56.43; H, 4.58; N, 15.35. Found: C, 56.54; H, 4.66; N, 15.26. IR (KBr, cm⁻¹): 685, 760 (C-

Cl), 825, 1305, 1375, 1520, 1695, 3055, 3245. ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.34 (s, 3H, -CH₃), 2.65 (s, 2H, -S-CH₂), 3.03 (t, 4H, -N-CH₂), 3.70 (s, 3H, -OCH₃), 3.95 (t, 4H, -N-CH₂), 5.85 (s, 1H, -N-CH), 6.85-7.55 (m, 11H, Ar-H), 11.05 (s, 1H, -NH).

3-(6-(4-(4-methoxyphenyl)piperazin-1-yl)-4-(*p*-tolyl oxy)-1,3,5-triazin-2-ylamino)-2-(3,4-dihydroxyphenyl)thiazolidin-4-one (C₅)

Yield 81%; m.p. 120-122 °C; Anal. Calcd. for C₃₀H₃₁O₅N₇S (601.67 gm/mole): C, 59.89; H, 5.19; N, 16.30. Found: C, 59.79; H, 5.31; N, 16.18. IR (KBr, cm⁻¹): 691, 823, 1308, 1385, 1525, 1695, 3045, 3246, 3280 (O-H). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.32 (s, 3H, -CH₃), 2.79 (s, 2H, -S-CH₂), 3.17 (t, 4H, -N-CH₂), 3.83 (s, 3H, -OCH₃), 3.93 (t, 4H, -N-CH₂), 5.35 (s, 1H, -OH), 5.65 (s, 1H, -OH), 5.95 (s, 1H, -N-CH), 6.70-7.40 (m, 12H, Ar-H), 11.10 (s, 1H, -NH).

Scheme - I



Scheme - II





Table-I: Antimicrobial activity of the synthesized compounds

Compound No.	Minimal Inhibitory Concentration (µg/ml)						
	Antibacterial Activity				Antifungal Activity		
	Gram (+ve) bacteria		Gram (-ve) bacteria		Gram (+ve) fungus	Gram (-ve) fungus	
	<i>S. aureus</i>	<i>S. pyogenus</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>C. albicans</i>	<i>A. niger</i>	<i>A. clavatus</i>
A ₁	25	100	25	50	100	200	100
A ₂	50	50	50	25	50	50	100
A ₃	100	50	100	50	50	100	25
A ₄	25	50	25	100	50	200	50
A ₅	50	100	50	50	25	100	100
B ₁	50	50	200	200	200	25	100
B ₂	100	50	100	50	100	25	50
B ₃	200	25	50	50	200	100	200
B ₄	25	50	25	100	50	100	200
B ₅	50	200	100	200	25	200	100
C ₁	50	100	25	50	200	100	50
C ₂	100	50	200	25	100	50	100
C ₃	200	50	100	100	25	50	50
C ₄	25	25	50	200	50	25	25
C ₅	50	100	25	50	100	100	100
Gentamycin	25	5	5	25	-	-	-
Nystatin	-	-	-	-	25	5	25



Results and Discussion

The synthetic route of the compounds (A, B & C) is outlined in schemes I & II respectively. The synthesis of 2-(2-substituted benzylidenehydrazinyl)-6-(4-(4-methoxyphenyl) piperazin-1-yl)-4-(*p*-tolyl)-1,3,5-triazine (A₁ to A₅) as shown in Scheme-I was carried out from *p*-cresol and cyanuric chloride. The compound-I and *N*-phenyl piperazine was refluxed to give compound-II which on refluxed with hydrazine hydrate in alcohol to give compound-III. The compound-III was refluxed with different substituted benzaldehyde to give (A₁ to A₅). The compound (B₁ to B₅) was synthesized by the reaction of (A₁ to A₅) with chloroacetylchloride in presence of base. The Compound (C₁ to C₅) was synthesized by thioglycolic acid and compound (A₁ to A₅) as shown in scheme-II.

The structures of the synthesized compounds were characterized by analytical methods and spectral data (IR and ¹H NMR). In the IR spectra, the -N=C bands were observed at 815, 1365, 1580 cm⁻¹. Compounds (A₁ to A₅) have shown -CH=N band in the range of 1600-1670 cm⁻¹. In compound (B₁ to B₅) C-Cl and C=O bands have shown at 780-830 cm⁻¹ and 1590-1750 cm⁻¹ respectively. In compound (C₁ to C₅) C-S-C bands were observed in the range of 670-720 cm⁻¹. In the ¹H NMR spectra range 3.70-4.20 ppm and 9.00-11.00 ppm (singlet) peaks for all compounds confirmed the availability of -OCH₃ and -NH group respectively. In compound (B₁ to B₅)-CH-Cl peaks at 4.58-4.71 ppm (singlet). In (C₁ to C₅) -S-CH₂ peaks at 3.70-3.95 ppm (singlet).

The antimicrobial activities of the synthesized compounds are also shown in the table III. The antimicrobial activities of these compounds active against variety of bacterial stains in

which some of these derivatives exhibited potential antibacterial and antifungal activity. The antimicrobial activities of the synthesized compounds are shown in the Table-I which were found moderate to good active against tested organism. Compounds A₁, A₄, B₄ & C₄ showed good activity (25µg/ml) against *S.aureus* compared to Gentamycin which may be due to 4-chloro, and 2,4-dichloro substituents. Compounds B₃ & C₄ showed good activity against *S.pyogenus* which may be due to 3-methoxy and 2,4-dichloro substituents. Compound A₁, A₄, B₄, C₁ & C₅ showed good activity (25µg/mL) against *E.coli* which possess due to 4-chloro, 3,4-dihydroxy and 2,4-dichloro substituents. Compounds A₂ & C₂ exhibited good activity (25µg/ml) against *P.aeruginosa* which possess due to 2-hydroxy substituent. Compounds A₅, B₅ & C₃ exhibited good activity against *C.albicans* compared to Nystatin which may be due to 3-methoxy, 3,4-dihydroxy substituents. Compounds B₁, B₂ & C₄ showed good activity against *A.niger* which may be due to 4-chloro, 4-hydroxy and 2,4-dichloro substituents. Compounds A₃ & C₄ showed good activity against *A.Clavatus* which possess due to 3,4-dihydroxy and 2,4-dichloro substituents. From the antibacterial and antifungal results (table-I) indicated that rest of all compounds moderate to weak activity against these species.

Antimicrobial activity

All the synthesized compounds (A, B & C) were screened for their antimicrobial activity by agar disc diffusion method^[15,16]. DMSO was used as diluents to get desired concentration of drugs to test upon standard bacterial strains. Serial dilutions were prepared in primary and secondary screening. All the tubes not showing visible growth are subcultured and incubated overnight at 37 °C. The tubes were then incubated overnight. The MIC of the control organism was read to check the accuracy of the drug concentrations. Prepared stock solution of antibiotics of concentrations 2000 mg/lit, as required. Arrange micro well plate 8×12 well of sterile well in the rack. The lowest concentration inhibiting growth of the organism was recorded as the MIC. The growth, inhibition is measured and compound is applied in the method to determine

the activity in µg/ml concentration. All the compounds were screened against Gram (+ve) bacteria [*Staphylococcus aureus* (MTCC-96) and *Streptococcus pyogenus* (MTCC-443)] and Gram (-ve) bacteria [*Escherichia coli* (MTCC-442) and *Pseudomonas aeruginosa* (MTCC-441)]. The antifungal activity was tested against Gram (+ve) fungus [*Candida albicans* (MTCC-227)] and Gram (-ve) fungi [*Aspergillus niger* (MTCC-282) and *Aspergillus clavatus* (MTCC-1323)]. The results of all the synthesized compounds were compared with Gentamycin and Nystatin as a reference drugs. The results are shown in table-I.

Conclusion

The antimicrobial activity of the synthesized compounds showed that compounds containing 4-hydroxy, 4-chloro and 2,4-dichloro substituents are found active against tested organism. This fact reveals that the activity is not affected due to the electronic properties of the substituents. Compounds A₁ & A₄ Schiff's base, B₄ azetidinone and C₄ thiazolidinone were found more active against these gram (+ve) and gram (-ve) bacterial and fungul species.

Acknowledgments

The authors are thankful to the Principal, Silvassa Institute of Higher Learning, Silvassa for providing the research facilities. The authors express their thanks and gratefully to the SAIF, Chandigarh for carrying out elemental analyses and ¹H-NMR spectra. The authors are also thankful to the Department of Chemistry, VNSG University, Surat for recording the IR spectra and for providing laboratory facilities.

References

1. R. Böhme, Qun Dang "1,3,5-Triazine" in Encyclopedia of Reagents for Organic Synthesis John Wiley & Sons 2008.

2. A. Aksenov, I. Aksenova, *Chemistry of Heterocyclic Compds.* 45(2) (2009) 130.
3. A. Rosowsky and S. Queener, *J. Med. Chem.*, 47 (2004) 1475.
4. C. Zhou, J. Min, Z. Liu, A. Young, H. Desharzer, T. Gao, Y. Chang and N. Kallenbach., *Bioorg. Med. Chem. Lett.*, 18(4) (2008) 1308.
5. M. Saleh, S. Abbott, V. Perron, C. Lauzon, C. Penney, B. Zacharie, *Bioorg. Med. Chem. Lett.*, 20 (2010) 945.
6. H. Tappe and P. Vermehren, *Ullman's Encyclopedia of Industrial Chemistry*, 651 (1989) A22.
7. D. Ludovici and R. Kavash, *Bioorg. Med. Chem. Lett.*, 11 (2001) 2229.
8. I. Gilbert and R. Brun, *J. Med. Chem.*, 44 (2001) 3440.
9. A. Agarwal and M. Chauhan, *Bioorg. Med. Chem. Lett.*, 15 (2005) 531.
10. M. Zheng, C. Xu, J. Ma, Y. Sun, F. Du, H. Liu, L. Lin, C. Li, J. Ding, K. Chen and H. Jiang., *Bioorg. Med. Chem.*, 15(4) (2007) 1815.
11. G. Kuo and X. Chen., *J. Med. Chem.*, 48 (2005) 4535.
12. K. Arya and A. Dandia, *Bioorg. Med. Chem. Lett.*, 17 (12) (2007) 3298.
13. J. Dudley, J. Thurston, F. Fchaefer, J. Hull, *J. Med. Chem.*, 73 (1951) 2986.
14. A. Baliani, G. J. Bueno, M. L. Stewart, V. Yardley, R. Brun, M. P. Barrett and I. H. Gilbert, *J. Med. Chem.*, 48 (17) (2005) 5570.
15. A. Rattan, *Antimicrobials in laboratory medicine*, B. I. Churchill, Livingstone, New Delhi (2000) 85–110.
16. R. Patel and K. Patel, *Experimental Microbiology Part 1 & 2*; Aditya Publication, Ahmedabad, 2004.